Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

Inclusion Criteria:

1. Subject is a male or non-pregnant female 18 years of age or older.

2. Subject has provided written informed consent.

3. Subject has a clinical diagnosis of stable mild to moderate plaque psoriasis for at
least two months.

4. Females must be post-menopausal , surgically sterile , or use an effective method of
birth control. Women of childbearing potential (WOCBP) must have a negative urine
pregnancy test (UPT) at Visit 2/Baseline.

5. Males (or their female partner) must agree to use an effective method of birth control
throughout the study.

6. Subject has two similar contralateral Target Plaques.

7. Subject is willing and able to apply the test article(s) as directed, comply with
study instructions, and commit to all follow-up visits for the duration of the study.

8. Subject, in the investigator's opinion, is in good general health and free of any
disease state or physical condition that might impair evaluation of the plaque
psoriasis or exposes the subject to an unacceptable risk by study participation.

Exclusion Criteria:

1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

2. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

3. Subject has guttate, pustular, erythrodermic, inverse, or other non-plaque forms of
psoriasis.

4. Subject has psoriasis beyond the two Target Plaques that, in the investigator's
opinion, could not be reasonably managed with only a bland emollient during the study.

5. Subject is currently enrolled in an investigational drug or device study.

6. Subject has been previously enrolled in this study and treated with test article.

Other protocol-defined inclusion and exclusion criteria assessed by the study staff may
apply.